Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Sosei Group ( (JP:4565) ) is now available.
Nxera Pharma has announced a proposal to amend its Articles of Incorporation to allow for virtual-only general meetings of shareholders, aligning with recent legislative changes and the digitalization of society. This move aims to enhance flexibility and reduce risks associated with physical meetings, benefiting shareholders and potentially strengthening the company’s operational resilience.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines to address unmet patient needs in Japan and globally. The company has a robust pipeline of over 30 active programs across neurology, gastrointestinal and immunology, metabolic disorders, and rare diseases, leveraging its proprietary GPCR-targeted structure-based drug discovery platform, NxWave. With operations in major cities including Tokyo, Osaka, London, and Cambridge, Nxera Pharma is listed on the Tokyo Stock Exchange.
YTD Price Performance: -1.67%
Average Trading Volume: 614
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $585.8M
See more data about 4565 stock on TipRanks’ Stock Analysis page.
